Show simple item record

dc.contributor.authorMakowska, Marta
dc.contributor.authorJasiński, Łukasz
dc.description.abstractThe article raises issues of transparency in relationships between doctors and drug manufacturers. It indicates how important it is as a way for physicians and the pharmaceutical industry to regain public trust. The manuscript will define the concept of disclosure. It will discuss in detail The Physician Payment Sunshine Act from the U.S., which imposes a legal obligation on pharmaceutical companies to disclose their relationships with doctors and university hospitals. The article will also show the diverse regulation of disclosure in different countries of the European Union. The situation in Poland will be also described. In the summary, there will be a discussion about the importance of disclosure for patients and the advantages and disadvantages of such regulations for physicians and drug manufacturers.en_GB
dc.description.sponsorshipPublication of English-language versions of the volumes of the "Annales. Ethics in Economic Life" financed through contract no. 501/1/P-DUN/2017 from the funds of the Ministry of Science and Higher Education devoted to the promotion of scholarship.en_GB
dc.publisherWydawnictwo Uniwersytetu Łódzkiegoen_GB
dc.relation.ispartofseriesAnnales. Ethics in Economic Life; 5
dc.rightsThis work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.en_GB
dc.subjectconflict of interesten_GB
dc.subjectethical standarden_GB
dc.subjectpharmaceutical industryen_GB
dc.titleThe importance of “disclosure” in relationships between physicians and pharmaceutical companiesen_GB
dc.contributor.authorAffiliationWarsaw University of Life Sciences, Faculty of Social Sciences, Department of Sociology
dc.contributor.authorAffiliationMaria Curie Skłodowska University of Lublin, Faculty of Economics
dc.referencesAdvaMed. (n.d.) The Physician Sunshine Act and you.
dc.referencesAgrawal, S., Brennan, N., & Budetti, P. (2013). The Sunshine Act—effects on physicians. New England Journal of Medicine, 368(22), 2054–2057.en_GB
dc.referencesAmerican Medical Association. (n.d.). Sunshine Act FAQs.
dc.referencesBelluz, J. (2014, September 30). Doctors and hospitals got at least $3.5 billion from industry in just five months. Vox.
dc.referencesCampbell, E. C., Gruen, R. L., Mountford, J., Miller, L. G., Cleary, P. D., & Blumenthal, D., (2007). A National Survey of Physician – Industry Relationships. The New England Journal of Medicine, 356, 1742–1750.en_GB
dc.referencesCBOS [Centre for Public Opinion Research]. (1999). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.en_GB
dc.referencesCBOS [Centre for Public Opinion Research]. (2013). Prestiż zawodów [Prestige of profession]. Warszawa: CBOS.en_GB
dc.referencesCBOS [Centre for Public Opinion Research]. 2016. Społeczne oceny uczciwości i rzetelności zawodowej [Social evaluation of honesty and professional integrity]. Warszawa: CBOS.en_GB
dc.referencesCenters for Medicare & Medicaid Services. (n.d.) Fact Sheet for Physcians, .pdfen_GB
dc.referencesCenters for Medicare & Medicaid Services. (n.d.) Open Payments Data Summary.
dc.referencesCiadini, R. (2003). Wywieranie wpływu na ludzi. Teoria i praktyka. Gdańsk: Gdańskie Wydawnictwo Psychologiczne.en_GB
dc.referencesThe CMS Blog. (2016). CMS Releases Third Year of Open Payments Data.
dc.referencesDhuri, S. (2013). Comparison of the French sunshine act. (Loi Bertrand Law) and the US Sunshine Act.
dc.referencesHajnosz, I., & Wróblewski, H. (2007). To jak pan korumpował lekarza. Gazeta Wyborcza, 182, p. 6.en_GB
dc.referencesHalperin, E. C., Hutchison, P., & Barrier Jr, R. C. (2004). A population-based study of the prevalence and influence of gifts to radiation oncologists from pharmaceutical companies and medical equipment manufacturers. International Journal of Radiation Oncology • Biology • Physics, 59(5), 1477–1483.en_GB
dc.referencesINFARMA. (2008). Kodeks Dobrych Praktyk Przemysłu Farmaceutycznego [Code of Good Practice of the Pharmaceutical Industry]. http://www.infarma. pl/assets/files/etyka/KodeksDobrych Praktyk_Wyd_2_201014_PL.PDFen_GB
dc.referencesINFARMA. (2015). Kodeks przejrzystości [Transparency Code],
dc.referencesINFARMA. (2015–2017). Raport przejrzystości.
dc.referencesINFARMA. (2016). Czym jest Kodeks Przejrzystości.
dc.referencesKruczkowska, M. (2013). Koncerny farmaceutyczne korumpują Chiny. Jeden się pokajał. Gazeta Wyborcza, 172, 8.en_GB
dc.referencesLieb, K., & Scheurich, A. (2014). Contact between doctors and the pharmaceutical industry, their perceptions, and the effects on prescribing habits. PLoS One, 9(10). doi: 10.1371/journal.pone.0110130en_GB
dc.referencesLizut, M. (2006). Jak ustawić lekarza. Gazeta Wyborcza, 120, 4.en_GB
dc.referencesMakowska, M. (2010). Etyczne standardy marketingu farmaceutycznego. Warszawa: CeDeWu.en_GB
dc.referencesMakowska, M. (2012). Rola śledztw dziennikarskich w kreowaniu etycznych standardów marketingu farmaceutycznego. Prakseologia, 152, 125–144.en_GB
dc.referencesMakowska, M. (2016). Etyczne wyzwania współpracy studentów medycyny z przemysłem farmaceutycznym. Studium porównawcze sytuacji w USA i Polsce. Warszawa: Wydawnictwo Szkoły Głównej Gospodarstwa Wiejskiego.en_GB
dc.referencesMarkowska, M., & Jasiński, Ł. (2017). Znaczenie „przejrzystości” w relacjach lekarzy z firmami farmaceutycznymi. Annales. Ethics in Economic Life, 20(1), 95–109.en_GB
dc.referencesMcDermott, Will & Emery. (2014). Snapshot of sunshine rules in EU countries for the pharmaceutical industry.
dc.referencesOrlowski, J. P., & Wateska, L. (1992). The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest, 102(1), 270–273.en_GB
dc.referencesPham-Kanter, G., Alexander, G. C., & Nair, K. (2012). Effect of physician payment disclosure laws on prescribing. Archives of Internal Medicine, 172(10), 819–821.en_GB
dc.referencesPolicyMed. (2016). Open Payments Data Summary. ments-2015-data-released.htmlen_GB
dc.referencesProzilo Life Sciences. (2015). Ready or Not, Full Speed Ahead for the Global Transparency Movement.
dc.referencesRabij, M., (2014). Lekarz zdalnie sterowany. Newsweek Polska, 2, 32–35.en_GB
dc.referencesSzymborski, T. (2003). Kasa fundacji zabytków. Rzeczpospolita, 123, A1–A4.en_GB
dc.referencesWazana, A. (2000). Physicians and the pharmaceutical industry. Is a gift ever just a gift? Journal of American Medical Association, 283(3), 373–380.en_GB
dc.referencesZverejňovanie na základe zákona č. 362/2011 Z. z. o liekoch a zdravotníckych pomôckach.

Files in this item


This item appears in the following Collection(s)

Show simple item record

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.
Except where otherwise noted, this item's license is described as This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.